- Trial phase
- Phase 2
- Time to market
- PDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.
- Why 4/10
- PDS0301 is a Phase 2 asset with no hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. The next company-level catalyst is Q3 2026 earnings on November 12, 2026, but that is a financial update, not a drug-specific binary. The drug is now the company's sole internally-funded asset following the August 2026 strategic refocus, but its mid-stage status limits the near-term share-price impact potential.
PDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.
Price Chart
Executive Summary
PDS0301 (also known as PDS01ADC) is a tumor-targeted immunocytokine (IL-12 antibody fusion) being developed by PDS Biotechnology Corp (Nasdaq: PDSB) for metastatic colorectal cancer (mCRC) with liver metastases. In August 2026, the company made PDS0301 its sole internally-funded asset, discontinuing its Phase 3 PDS0101 head-and-neck cancer program after Phase 2 data showed a 71% overall response rate in mCRC patients with liver metastases. The stock crashed roughly 67% on the news. A subsequent $22.3M PIPE financing led by Dr. Patrick Soon-Shiong's Nant Capital in September 2026 provided capital and board-level strategic support. PDS0301 is still in Phase 2 development with no hard dated binary catalyst (PDUFA or pivotal readout) scheduled in the next 12 months. The stock trades near $1.03 with a mean analyst price target of $4.50, reflecting strong bullish sentiment from covering analysts, but the single-asset, pre-revenue profile carries high execution and financing risk.
How It Works
PDS0301 (also called PDS01ADC) is a tumor-targeted immunocytokine, a type of antibody-drug conjugate. It fuses a tumor-targeting antibody to interleukin-12 (IL-12), a potent immune-signaling protein. The antibody portion homes in on the tumor, delivering IL-12 directly into the cancer microenvironment. This stimulates the patient's own immune T cells and natural killer cells to attack the tumor while limiting the systemic side effects that free IL-12 would cause. In plain terms, it is a guided missile that delivers an immune-boosting payload straight to the cancer.
Trial Status
PDS0301 has generated Phase 2 data in metastatic colorectal cancer (mCRC) with liver metastases showing a 71% overall response rate in an NCI-led investigator-sponsored trial. A separate Phase 2 study (NCT05286814) of PDS01ADC combined with HAIP FUDR showed a 77.8% 6-month ORR in mCRC liver-metastasis patients. The drug has also been studied in a Phase 1/2 trial for metastatic prostate cancer in combination with docetaxel. The company held a KOL event on October 15, 2026, to discuss the mCRC data and development path.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings call on November 12, 2026, where management may provide PDS0301 development updates and cash runway guidance
- Potential End-of-Phase 2 FDA meeting to discuss registrational path for PDS0301 in mCRC with liver metastases
- Additional Phase 2 data readouts from ongoing NCI-led trials in mCRC and potentially other indications
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PDS Biotechnology Corp 8-K PDSB ·Originating report